Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging

Launched by YALE UNIVERSITY · Jun 7, 2023

Keywords

ClinConnect Summary

The CAPTIVA-MRI clinical trial is studying the best ways to treat patients who have had a stroke due to narrowing of the blood vessels in the brain, specifically looking at a condition called intracranial atherosclerotic stenosis (ICAS). The main goal is to see if special MRI scans can help identify patients who are not responding well to standard treatments. This study is part of a larger trial that compares different blood-thinning medications to find the most effective one for preventing future strokes.

To be eligible for this trial, participants must have experienced a mild stroke within the last 30 days due to significant narrowing of certain brain arteries. They also need to be able to have an MRI scan within two weeks of joining the main trial. Those with certain medical conditions that prevent them from having an MRI or who are allergic to the contrast dye used in some scans may not qualify. If you participate, you can expect to have an MRI as part of the study, which will help researchers understand how to better manage and treat patients with this condition in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Enrollment in the CAPTIVA trial: nondisabling symptomatic ischemic infarct stroke within 30 days secondary to 70-99% stenosis of the intracranial ICA, MCA, BA or VA
• • Ability to obtain baseline study MRI within 14 days of CAPTIVA enrollmen
• Exclusion Criteria:
• • Unable or unwilling to undergo MRI, including pacemaker or other MRI contraindications per American College of Radiology guidelines62
• • Gadolinium contrast allergy or acute or chronic kidney disease with eGFR\<30 ml/min/1.73m2